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Abstract 
Background 
Estimating harm rates for specific patient populations and detecting significant changes in 
them over time are essential if patient safety in general practice is to be improved. Clinical 
record review (CRR) is arguably the most suitable method for these purposes, but the optimal 
values and combinations of its parameters (such as numbers of records and practices) remain 
unknown. Our aims were to: 1. Determine and quantify CRR parameters; 2. Assess the 
precision and power of feasible CRR scenarios; and 3. Quantify the minimum requirements 
for adequate precision and acceptable power. 
Method 
We explored precision and power of CRR scenarios using Monte Carlo simulation. A range 
of parameter values were combined in 864 different CRR scenarios, 1000 random data sets 
were generated for each, and harm rates were estimated and tested for change over time by 
fitting a generalised linear model with a Poisson response. 
Results 
CRR scenarios with ≥100 detected harm incidents had harm rate estimates with acceptable 
precision. Harm reductions of 20% or ≥50% were detected with adequate power by those 
CRR scenarios with at least 100 and 500 harm incidents respectively. The number of detected 
harm incidents was dependent on the baseline harm rate multiplied by: the period of time 
reviewed in each record; number of records reviewed per practice; number of practices who 
reviewed records; and the number of times each record was reviewed. 
Conclusion 
We developed a simple formula to calculate the minimum values of CRR parameters required 
to achieve adequate precision and acceptable power when monitoring harm rates. Our 
findings have practical implications for health care decision-makers, leaders and researchers 
aiming to measure and reduce harm at regional or national level. 
Keywords 
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Background 
It is now generally accepted that a significant minority of patients may suffer preventable 
harm as a result of their interaction with health care [1]. In response, improving patient safety 
has become a national priority of most modern health care systems, including the National 
Health Service (NHS) in the United Kingdom (UK). Initial efforts were mainly directed at 
acute hospitals, but the improvement and research focus are now being widened to include 
other care settings, including primary care and general medical practice [2,3]. 
To begin to consider how to measure and improve the safety of general practice, at least two 
important challenges have to be considered. Although a number of explicit patient safety 
risks have been identified, the incidence of harm in primary care has not yet been quantified 
reliably [4]. This is essential to understand the scale of the safety problem and to inform the 
design and implementation of improvement initiatives. The second challenge is to evaluate 
the impact of these interventions through serial monitoring to determine if improvement 
efforts are beneficial and leading to safer care or to otherwise adapt them to ensure they are. 
The retrospective review of clinical records may offer a consistent and widely applicable 
approach to solving both of these problems. The findings of landmark studies utilizing this 
approach have shaped our understanding of the scale of the problem in secondary care 
settings worldwide and this evidence was the primer for the development and implementation 
of national policies to make patient care safer [5,6]. Clinical record review (CRR) is a well-
established approach to detecting and quantifying sub-optimal care issues [7,8]. CRR allows 
estimation of harm rates for specific patient populations at given points in time and, if 
repeated, allows comparisons to detect significant changes across time. Other methods such 
as incident reporting systems and analyzing complaints are methodologically limited by 
comparison as regarding to this specific aspect because they rely on self-report data or 
typically focus on only a small sub-set of the patient population [9-12]. 
The CRR method is flexible with no single ‘correct’ adaptation. In recent years the Institute 
for Healthcare Improvement (IHI) has popularized the ‘global trigger tool’ as a means for 
frontline clinicians to estimate harm rates using this rapid, focused and structured approach to 
record review [13]. Their rationale for the trigger tool method is ‘…the ability to quantify 
[harm] accurately with relatively small samples [of medical records] and to follow changes 
[in harm rates] longitudinally over time… [12]’ 
Specific trigger tools are now routinely used in many acute hospital settings worldwide [13-
16] and have been piloted in other settings including primary care [17-20] to test their 
feasibility in measuring rates of harm. However, the reliability (and therefore potential 
usefulness) of these measures is dependent on a large number of CRR parameters including: 
(i) the quality of the clinical records; (ii) individual reviewer factors (inter-rater reliability, 
quality and intensity of previous training and experience, and if the reviewer is internal or 
external to the practice and if one or more individuals review each record); (iii) specific 
characteristics of the review process (number of months or encounters reviewed in each 
record, how many records are reviewed and how often reviews are conducted) and (iv) the 
‘frailty’ of the patient population whose records are reviewed (inter-patient and inter-practice 
variation, which reflects the likelihood of patients experiencing harm) [13-20]. 
It remains unclear which combinations of these parameters represent suitable robust and 
rigorous review methods to ensure their harm rate estimates are sufficiently precise and have 
adequate statistical power to differentiate actual changes from random variation. 
Unfortunately this crucial point is often overlooked by researchers and policy makers who 
appear to accept any harm rate estimate or reduction at face value. Therefore, while the 
record review method and its various adaptations may potentially be of great use, it is 
essential to first resolve this methodological and statistical challenge. The aims of this study 
were therefore to: 
1. Describe the parameters which constitute a CRR and select a range of values 
representative of and feasible in a general practice setting; 
2. Assess the levels of precision and power of harm rate monitoring yielded by the different 
CRR scenarios; 
3. Determine and describe the minimum requirements which ensure CRR harm rate estimates 
have adequate precision and acceptable power. 
Method 
Study design 
We chose Monte Carlo simulation to examine the levels of precision and power of harm rate 
estimates as measured by different general practice CRR scenarios. Monte Carlo simulation 
is often used to model non-deterministic systems with substantial inherent uncertainty, which 
makes it ideal for the general practice setting. The key advantage of this approach is that it 
can be used to investigate multiple complex ‘real-life’ scenarios not covered by conventional 
analytical approaches. Details of how harm incidents events were simulated are given in the 
Statistical Modeling section below. 
We identified the parameters that constitute a CRR, devised explicit assumptions about the 
range of parameter values that may be feasible in general practice and defined when CRR 
harm rate estimates would be considered to have acceptable precision and adequate power. 
Precision and power of harm rate estimates 
CRR harm rate estimates can be used in two different ways. Firstly, to quantify the incidence 
of harm in defined patient populations at given points in time (e.g. the number of 
unintentional harm incidents detected in the clinical records of a population of patients with 
diabetes mellitus). The findings are expressed as a rate such as ‘number of harm incidents per 
100 patients per year’. Secondly, harm rate estimates at different points in time can be 
compared to detect increases or reductions, with observed changes expressed as percentages. 
Precision 
The precision of a harm rate estimate is its repeatability, that is, the degree to which it is 
subject to random sampling error. We used ‘estimation error’ as a proxy for precision (low 
estimation error implying high precision) because it is easier to quantify and interpret. 
Estimation error was defined as the distance from the 95% confidence limits to the estimate 
(expressed as a percentage). For example, a harm rate of 10 incidents/100patients/year with a 
95% confidence interval (CI) of 8–12 could also be expressed as 10 ±2. Expressing ±2 as a 
percentage of 10 gives an estimation error of ±20%. 
A high level of precision (indicative of low estimation error) is a desirable property of any 
estimate, but may require substantial resources (e.g. more time, multiple reviewers and larger 
numbers of patient records). The converse is true for estimates with low levels of precision 
(high estimation errors). We pragmatically defined ‘acceptable precision’ of a harm rate 
estimate as an estimation error less than ±25%. In other words, any CRR harm rate estimate 
within ±25% of the estimated harm rate. 
Power 
In statistical terms, power is defined as the probability that a test will correctly reject the null 
hypothesis of no change when it is false. In the context of our study, power gauges how likely 
specific CRR scenarios were to detect real changes in harm rates over the simulated 12-
month period. We defined ≥80% power as adequate as per convention. 
CRR parameters 
We identified parameters and chose a realistic range of fixed and variable values which may 
affect the precision and power associated with CRR results (Table 1). 
Table 1 Simulated clinical record review (CRR) parameters and parameter values and 
their effect on the precision and power of harm rate estimates 
Parameters Selected 
parameter values 
Parameter 
affects 
precision 
Parameter 
affects power 
Parameters with variable values    
Number of general practices conducting 
CRR 
1, 10, 20, 50, 100, 
150, 200, 250, 300 
√ √ 
Number of unique patient records 
reviewed by each practice at a given 
point in time 
20, 25, 50, 100, 
150, 200 
√ √ 
The real harm rate in the sampled 
patient population, expressed as 
incidents per 100 patients per year 
2, 5, 10, 20 √ √ 
The actual reduction in the real harm 
rate over twelve months 
20%, 50%  √ 
Inter-patient variation in harm 
susceptibility, expressed as a median 
rate ratio (MRR) 
1.2, 2 √ √ 
Parameters with fixed values    
Inter-practice variation in harm 
susceptibility, expressed as a MRR 
1.2 √ √ 
Period of time reviewer reviewed in 
each record (calendar months) 
3 √ √ 
Period of time over which changes in 
harm rates are examined (months) 
12  √ 
Number of reviews during the simulated 
12-month period 
2  √ 
Reviews at different time points are 
conducted on the same or different 
samples of patient records 
Same  √ 
The different parameters and parameter values can potentially be combined in 864 uniquely 
different CRR scenarios. 
Fixed parameter values 
We identified a number of fixed parameter values, based on previous experience of feasibility 
[21]; these were identical in every CRR scenario. The fixed parameters were: (i) the same 
internal clinical reviewer conducting reviews at (ii) two time points (the beginning and end) 
of a (iii) 12-month time interval using (iv) the same sample of patient records and (v) 
reviewing the preceding three calendar months in each unique patient record at each time 
point. 
Variable parameter values 
Our assumption of the real harm rates in different patient populations was based on previous 
research and covered a tenfold range from 2 to 20 incidents per 100 patients per year 
[1,17,18]. The lower harm rates represent a sample of patients from the whole practice 
population and the higher rates reflect more harm-prone samples such as elderly populations 
with multiple morbidities. 
The number of simulated practices participating in CRR ranged from a single practice to a 
maximum of 300. This choice was informed by the feasibility of sample size and that there 
are fewer general practices than this in any given NHS Scotland regional Health Board [22]. 
At both time points, an internal clinical reviewer in each simulated practice reviewed a 
number of records which ranged from 20 to 200. Twenty records is feasible for a single 
internal clinician reviewer [20,23], while reviewing 200 records per time point is entirely 
possible using external reviewers but will clearly require greater investment in terms of time, 
commitment, effort and funding. Harm rate reductions of 20% (relatively small) or 50% 
(relatively large) were chosen for the specified 12- month period. 
Patients differ in their risk of suffering harm and general practices differ in their risk of 
potentially causing iatrogenic harm. For example, elderly patients with multiple co-
morbidities and many repeat prescription items are more likely to suffer harm than healthy 
young adults who infrequently attend general practice. Additionally, there is variation 
between practices in the frailty of patient populations, and in adherence to safety protocols, 
effectiveness of team working and communication, safety culture perceptions and the content 
quality of available records in practices [24]. We accounted for these risk variations by 
introducing two additional parameters: inter-patient variation and inter-practice variation 
(inter-practice variation can also be viewed as correlation between patients within practices). 
These parameters are discussed below. 
Inter-patient and inter-practice variation 
We quantified inter-patient and inter-practice variation using median rate ratios (MRR) [25]. 
The MRR is the expected harm rate ratio between two randomly sampled patients or practices 
with otherwise identical characteristics. Because the MRR is always expressed as the ratio of 
the higher to the lower risk, it is always ≥ 1. Therefore an MRR of 1 implies that all patients 
or practices are equally likely to suffer or cause harm, while an MRR of 2 implies an average 
twofold difference in harm susceptibility. 
We assumed that even the most homogeneous population of practices and patients would 
differ in underlying harm rate to some degree, so chose a minimum MRR of 1.2. We assessed 
inter-patient variation in harm rate (the tendency for some patients to be more harm prone) 
MRRs of 1.2 and 2, representing relatively homogeneous and more diverse populations 
respectively. For practices we present results for MRR = 1.2 only, based on our preliminary 
analyses which suggested varying MRR among practices had little effect on the precision and 
power of harm rate estimates (compared with the effect of varying MRR among patients). 
Simulation of CRR scenarios 
We generated 1000 random data sets for each of the 864 possible combinations of the 
different parameter values. Each simulated data set recorded the number of harm incidents 
“observed” in each patient’s records, within each practice, at each timepoint. Each simulated 
data sets is intended to represent what may have been produced by an actual review in ‘real 
life’. We estimated the harm rate at both time points and tested for over a 12-month period 
for each data set, before averaging over all 1000 sets of results to give the expected 
estimation error and power for every record review scenario. Average estimation error was 
calculated using the median, while power was estimated as the percentage of the 1000 data 
sets where the test of the null hypothesis of no change in the harm rate was significant (P < 
0.05). Percentage estimation error was calculated as 100 × 0.5 × median confidence interval 
width divided by median harm rate estimate. Sampling error in the power and precision 
estimates was small because of the large number of data sets generated and we therefore for 
simplicity of presentation we do not show confidence intervals (CIs) around the estimates. 
We also simulated and analysed data under the null hypothesis of ‘no change’, which allowed 
us to validate the methodology by checking the type I error rate (results not shown). 
Simulation and modeling assumptions 
Because patients could potentially experience more than one harm incident during the review 
period, the number of detected events was treated as count rather than binary data and 
simulated and modelled as a Poisson random variable within the framework of a generalised 
linear model (GLM). In addition, the expectation of variation in underlying harm rates 
between patients and practices motivated the inclusion of random effects. We therefore 
simulated and modelled the number of harm incidents as a Poisson generalised linear mixed 
model (GLMM) with harm rates allowed to vary randomly between practices and patients, 
assuming a lognormal distribution for the random effects (the Poisson-lognormal model) 
[26]. The change in harm rate over the 12-month study period was simulated and modeled as 
a fixed effect and is presented as the percentage reduction in the real harm rate. 
Specifically, the number of harm incidents yijk detected during review of the records of 
patient i in practice j at time k was drawn from a Poisson distribution with harm rate λijk; that 
is, yijk ~ Pois(λijk). The effects of time, inter-patient and inter-practice variation influenced the 
harm rate additively on the log scale such that log(λijk) = α + βxijk + u1i + u2j where α is the 
overall mean log harm rate at the first review and β is the fixed effect of time. x indicates 
whether record review is taking place at the beginning (x = 0) or end (x = 1) of the twelve 
months period, so that the mean log harm rate is α at the first and α + β at the second review. 
u1 and u2 are patient- and practice-level random effects, respectively, that allow harm rate to 
vary between patients within practices and between practices.u1 and u2 are normally 
distributed with variances φ12 and φ22, respectively. 
Estimation and significance testing were carried out by fitting a GLM with a Poisson 
response [27]. This model does not allow adjustment for inter-practice and inter-patient 
variation (which we know to be present) and we therefore expected the model estimates to be 
biased. We initially attempted to adjust for both these sources of variation by fitting the same 
Poisson-lognormal GLMM that was used to simulate the data. However, in preliminary 
analyses we found that the number of harm incidents was too low, even at the highest harm 
rate, to allow the GLMM-fitting algorithm to converge on either the inter-practice or the 
inter-patient variance estimates.. 
Statistical analysis 
All analyses were performed in R version 2.14.0. GLMs were fitted using the glm function, 
while GLMMs were fitted using the glmer function in the lme4 package [28]. We confirmed 
that the failure of GLMMs to fit was not specific to the algorithm used by fitting a selection 
of models by penalised quasi-likelihood (using glmmPQL in R) [29] and Monte Carlo 
Markov Chain (using MCMCglmm in R) [30]. We assessed the validity of the fitted models 
by monitoring estimation bias, confidence interval coverage and type I error rate. 
A problem encountered when some of datasets were simulated with very low or no harm 
incidents at one or both visits then the model-fitting algorithm failed to converge and did not 
yield valid harm rate estimates or p-values. When estimating power, these refractory data sets 
were counted as yielding non-significant results. For the purpose of estimating CI width, 
estimates from these failed model fits were excluded from the calculation of the median, 
except when ≥10% of fits failed, in which case the average CI was not calculated for that 
CRR scenario. Such data sets were generated only when very low precision (estimation error 
> ±100%) and power (<20%) were expected, and therefore represent CRR scenarios that 
should be avoided when aiming to study, measure or monitor the incidence of harm in 
general practice. 
Results 
Precision of estimated harm rates 
Table 2 summarizes the estimation errors of selected CRR scenarios’ harm rate estimates. 
Figure 1 provides a graphical display of all CRR scenarios that yielded harm rate estimates 
with acceptable precision. Three parameters were varied in these CRR scenarios: (i) the 
number of practices reviewing records, (ii) number of records reviewed in each practice and 
(iii) the real harm rate (rHR) prevalent in the patient population at the beginning of the 12-
month period specified for this study. All reported results are for CRR scenarios with high 
inter-patient variation (MRR = 2). CRR scenarios with low inter-patient variation (MRR = 
1.2) are presented as supplementary tables and figures (Additional file 1). 
Table 2 The precision$ of selected clinical record review (CRR) scenarios’ estimated 
harm rates 
Practices (n) Records reviewed per practice (n) Estimation error (%)$ 
rHR* = 2 rHR* = 5 rHR* = 10 rHR* = 20 
1 20 - - - - 
25 - - - - 
50 - - - - 
100 - - - 107 
150 - - 132 88 
200 - - 107 74 
10 20 - - 107 74 
25 - 146 96 67 
50 - 96 65 46 
100 107 65 46 32 
150 88 54 37 26 
200 74 46 32 23** 
20 20 - 107 74 51 
25 - 96 65 46 
50 107 65 46 32 
100 74 46 32 23 
150 60 37 26 18 
200 51 32 23 16 
50 20 107 67 46 32 
25 96 58 41 29 
50 65 41 29 20 
100 46 29 20 14 
150 37 23 17 12 
200 32 20 14 10 
100 20 74 46 32 23 
25 65 41 29 20 
50 46 29 20 14 
100 32 20 14 10 
150 26 17 12 8 
200 23 14 10 7 
150 20 60 37 26 18 
25 54 33 23 17 
50 37 23 16 12 
100 26 17 12 8 
150 21 13 10 7 
200 18 12 8 6 
200 20 52 32 23 16 
25 46 29 20 14 
50 32 20 14 10 
100 23 14 10 7 
150 18 12 8 6 
200 16 10 7 5 
250 20 46 29 20 14 
25 41 26 18 13 
50 29 18 13 9 
100 20 13 9 6 
150 17 10 7 5 
200 14 9 6 5 
300 20 42 26 18 13 
25 37 23 17 12 
50 26 17 12 8 
100 18 12 8 6 
150 15 10 7 5 
200 13 8 6 4 
$Precision is expressed as percentage estimation error, averaged across 1000 simulated 
studies for each CRR scenario. 
*rHR (real harm rate): The actual, underlying ‘baseline’ harm rate, expressed as number of 
incidents/100 patients/year. The harm rates estimated by different CRR scenarios are not 
shown. 
**Example: In this CRR scenario, 10 practices each reviewed 200 records and the estimation 
error was ±23%, e.g. within ±23% of the rHR of 20 incidents/100patients/year. The 
estimation error (%) indicates the proximity between the harm rate estimated by that unique 
CRR scenario and the rHR. Smaller estimation errors therefore indicate greater precision. We 
defined acceptable precision as estimation errors < ±25%. 
Scenarios vary by numbers of practices reviewing records, number of records reviewed in 
each practice and real harm rates (rHR)*. The median rate ratios (MRR) between patients and 
practices are 2 and 1.2 respectively. The results are from the beginning of the simulated 12-
month period. 
Figure 1 Clinical record review (CRR) scenarios which yielded harm rate estimates with 
acceptable precision, e.g. estimation errors < ±25% of the real harm rate (rHR). The 
lines and the zone above and to the right of each line represent those CRR scenarios with 
acceptable precision. Scenarios vary according to number of practices reviewing records, 
number of records reviewed per practice and the rHR (indicated by numbers on the lines and 
measured in incidents/100 patients/year. The median rate ratios (MRR) between patients and 
practices are 2 and 1.2 respectively. The results are for the beginning of the simulated twelve 
month period. 
Different combinations of certain parameter values produced CRR scenarios which yielded 
harm rate estimates with acceptable precision. For a rHR of 20 incidents/100 patients/year, 
2000 unique patient records had to be reviewed in total to ensure the harm rate estimate had 
adequate precision. Table 2 and Figure 1 show that adequate precision was achieved by any 
combination of numbers of practices and records that yielded approximately 2000 records: 
ten practices x 200 records each; 20 practices x 100 records each; etc. 
For a rHR of 10 rather than 20 incidents/100 patients/year, the total number of records to 
review increased from 2000 (for example 10 practices x 200 records each, precision ±23%), 
to 4000 (e.g. 20 practices x 200 records each, precision ±23%) to ensure adequate precision 
of harm rate estimates. Again, the particular combination of numbers of practices and records 
required to reach this critical number of records was not important. Similarly, for rHR of 5 
and 2 incidents/100 patients/year, a total of 7500 (e.g. 50 practices x 150 records each, 
precision ±23%) and 20000 records (e.g. 100 practices x 200 records, precision ±23%) had to 
be reviewed to ensure adequate precision of harm rate estimates (Table 2, Figure 1). Put 
simply, lower real harm rates required CRR scenarios with greater numbers of records to be 
reviewed to ensure their harm rate estimates still had adequate precision. We noted that the 
constant factor across all scenarios giving adequate precision was the expected number of 
harm incidents, which was 100. 
CRR scenarios’ power to detect reductions in harm 
Table 3 shows the power (adequate or inadequate) of selected CRR scenarios, while Figure 2 
graphically displays all CRR scenarios with adequate power to detect reductions in harm over 
the specified period of twelve months. Four parameters were varied in these CRR scenarios: 
(i) the number of practices reviewing records, (ii) number of records reviewed in each 
practice; (iii) the real harm rate (rHR) prevalent in the patient population at the beginning of 
the twelve month period; and (iv) the reduction in the rHR (50% or 20%). 
Table 3 Power (%)* of selected clinical record review (CRR) scenarios to detect a 
reduction (R) in the real harm rate (rHR) over a twelve month period 
Practices 
(n) 
Records reviewed 
(n)** 
Power (%) 
rHR = 2 rHR = 5 rHR = 10 rHR = 20 
R = 
50% 
R = 
20% 
R = 
50% 
R = 
20% 
R = 
50% 
R = 
20% 
R = 
50% 
R = 
20% 
1 40 0 0 0 0 0 0 0 0 
50 0 0 0 0 0 0 0 0 
100 0 0 0 0 0 0 1 1 
200 0 0 0 0 2 1 9 5 
300 0 0 0 0 3 2 19 7 
400 0 0 1 1 11 4 27 7 
10 40 0 0 1 0 8 4 30 8 
50 0 0 2 1 16 5 37 8 
100 1 0 14 5 38 7 64 14 
200 9 4 36 8 66 13 93 22 
300 21 5 57 10 84 16 98 32 
400 28 8 65 12 91 22 100 41 
20 40 0 0 10 4 28 7 53 11 
50 0 0 17 6 37 8 66 15 
100 10 4 37 10 63 13 93 24 
200 28 7 67 13 91 22 100 38 
300 43 9 81 19 98 31 100 54 
400 56 11 92 20 100 40 100 69 
50 40 9 3 34 8 65 13 93 24 
50 14 5 45 10 75 16 96 28 
100 36 10 74 16 96 25 100 48 
200 64 12 97 27 100 48 100 79 
300 84$ 18$ 100 41 100 64 100 92 
400 94 21 100 48 100 79 100 97 
100 40 31 6 64 11 92 20 100 40 
50 35 10 76 14 96 29 100 53 
100 66 12 97 26 100 47 100 77 
200 90 22 100 48 100 76 100 96 
300 98 34 100 64 100 92 100 100 
400 100 38 100 78 100 97 100 100 
150 40 45 10 84 16 99 33 100 56 
50 51 11 89 21 100 38 100 64 
100 82 15 100 39 100 64 100 91 
200 99 32 100 64 100 91 100 100 
300 100 46 100 81 100 99 100 100 
400 100 57 100 92 100 100 100 100 
200 40 53 12 91 23 100 38 100 68 
50 64 12 96 28 100 47 100 77 
100 92 22 100 49 100 78 100 97 
200 100 36 100 79 100 96 100 100 
300 100 56 100 92 100 100 100 100 
400 100 67 100 96 100 100 100 100 
250 40 64 14 98 25 100 49 100 77 
50 76 13 99 36 100 58 100 85 
100 97 30 100 55 100 86 100 99 
200 100 50 100 87 100 99 100 100 
300 100 67 100 95 100 100 100 100 
400 100 79 100 99 100 100 100 100 
300 40 74 15 99 31 100 55 100 84 
50 82 18 99 37 100 64 100 90 
100 98 29 100 65 100 91 100 100 
200 100 54 100 91 100 100 100 100 
300 100 73 100 99 100 100 100 100 
400 100 85 100 100 100 100 100 100 
*Power below the type I error rate of 5% is possible because analyses where the estimates 
failed to converge are counted as failure to detect change in the harm rate. 
**The total number of records reviewed during the twelve month period is shown. Each 
patient record was reviewed twice during this time. 
$Example: In this CRR scenario, 50 practices each reviewed 300 records (150 at the 
beginning and 150 at the end of twelve months) and had a baseline rHR of 2 
incidents/100patients/year. Reductions of 50% and 20% over a twelve month period were 
detected with 84% (adequate) and 18% (inadequate) power respectively. 
Scenarios vary by numbers of practices reviewing records, number of records reviewed in 
each practice and rHR. Median rate ratios (MRR) between patients and practices are 2 and 
1.2 respectively. 
Figure 2 Clinical record review (CRR) scenarios with adequate power (≥80%) to detect 
a 50% (solid line) or 20% (dashed line) reduction in real harm rates (rHR) over a 12-
month period. The lines and the zone above and to the right of each line represent CRR 
scenarios with adequate power. Scenarios vary according to number of practices reviewing 
records, number of records reviewed per practice and the rHR (indicated by numbers on the 
lines and measured in incidents/100 patients/year. The median rate ratios (MRR) between 
patients and between practices were 2 and 1.2 respectively. 
Similar to precision, different combinations of parameter values produce CRR scenarios with 
adequate power. For a rHR of 20 incidents/100 patients/year reduced by 50%, any CRR 
scenario that required 2000 record reviews had adequate power (Table 3): 10 practices each 
reviewing 100 records twice; 20 practices each reviewing 50 records twice; 50 practices each 
reviewing 20 records twice. Figure 2 shows many other potential parameter value 
combinations which also produced CRR scenarios with adequate power. 
Smaller reductions and lower baseline (real) harm rates required CRR scenarios with 
increasing numbers of records to ensure adequate power. For a rHR of 10 instead of 20 
incidents/100 patients/year in the aforementioned example, the total number of records to 
review increased from 2000 to 3000 to ensure a 50% reduction was detected with acceptable 
power. For baseline harm rates of 5 or 2 incidents/100 patients/year, the total number of 
records reviewed increased further to approximately 6000 and 15000 respectively (Table 3, 
Figure 2). As with the results for precision, the critical factor in achieving adequate power to 
detect a 50% reduction in harm rate was the number of harm incidents that were expected to 
be observed, which was almost invariant at 75–100. 
Detection of a more modest 20% reduction required a fivefold increase in the number of 
reviewed records. For the same set of rHRs of 20, 10, 5 or 2 incidents/100 patients/year, CRR 
scenarios required reviewing 12 000, 25 000, 45 000 and 120 000 records, respectively. This 
translates into the relatively simple rule that there will be adequate power to detect a 20% 
reduction in harm rate if approximately 600 harm incidents are expected to be observed. 
A formula for precision and power 
Levels of precision and power were mainly determined by the number of harm incidents 
expected in any given CRR scenario. The number of harm incidents is in turn determined by 
the real harm rate (rHR) multiplied by the total time reviewed, across all patients, during the 
complete CRR process. The time and effort required to complete the CRR process is a 
product of: 1. the period of time reviewed in each record; 2. number of records reviewed per 
practice; 3. number of practices reviewing records; and 4. the number of times each record is 
reviewed. The relationship between the number of detected harm incidents and CRR 
parameters can be simplified and expressed as a formula (Figure 3). 
Figure 3 A formula to express the relationship between the parameters of CRR 
scenarios and their numbers of detected harm incidents, which is associated with the 
precision and power of estimated harm rates. $We specified a three month period of 
review in each record for the purposes of this study. In our examples this is expressed as 0.25 
years. Increasing the review period from three to twelve months would have resulted in a 
fourfold reduction in the number of records each practice had to review. *The levels of 
precision and power we selected for the purposes of this study. **The values of rHR, nPrac 
and nRec are taken from the ‘lines’ in Figures 1 and 2. 
Substituting the numbers which constitute the ‘lines’ in Figures 1 and 2 (the number of 
practices reviewing records, number of records being reviewed per practice and the real harm 
rates) into this formula resulted in a ‘constant’ number of detected harm incidents. This 
‘constant’ is the minimum number of harm incidents which had to be detected during any 
CRR process to ensure acceptable precision or adequate power of its estimated harm rates. 
We found that any CRR scenario (e.g. any combination of record review parameters and 
parameter values) that result in at least 100 harm incidents being detected will have harm rate 
estimates with acceptable precision (as defined by us). Reductions of ≥ 50% in harm were 
detected with adequate power by any CRR scenario which ensured at least 100 harm 
incidents were detected during the specified time period (twelve months). However, to detect 
a 20% reduction, CRR scenarios had to allow detection of a minimum of 500 harm incidents. 
Estimating harm in a single general practice 
It is evident from Figures 1 and 2 that no combination of parameter values yielded a global 
harm rate estimate with acceptable precision or adequate power for a single general practice. 
For a practice that reviewed 200 records and assumed a relatively high rHR of 20 
incidents/100 patients/year, the estimated error was ±74% (Table 2). If the practice reviewed 
the 200 records for a second time, twelve months later, their CRR strategy would have 27% 
and 7% power to detect a 50% and 20% reduction in the rHR respectively (Table 3). Using 
the formula (Figure 3), and assuming a rHR of 20 incidents/100patients/year and a 50% 
reduction in harm, we calculated that a practice would have to review a minimum of 2000 
records to ensure their estimated global harm rate had acceptable precision and adequate 
power. 
Inter-patient variation and bias 
Bias was a substantial influence on the harm rate estimates of those CRR scenarios with high 
inter-patient variation (MRR = 2), being typically around 30% (Additional file 1: Table S3; 
median bias across all scenarios: 28%; interquartile range: 23% to 30%). For example, the 
CRR scenario in Table 2 with a rHR of 20 incidents/100 patients/year and 20 practices each 
reviewing 100 records had adequate precision (estimation error = 24%). However, this 
estimation error does not include bias, which for this CRR scenario was 30%. Combining 
precision and bias, a typical harm rate estimate for this CRR scenario would be 26 (95% CI 
19.5-32.5) incidents/100 patients/year. Where inter-patient variation was low (MRR = 1.2), 
bias was insignificant or absent (Additional file 1: Table S3; median bias across all scenarios: 
0%; interquartile range: -4% to 2%). Inter-patient variation had no significant impact on 
power to detect a reduction in harm rates. 
Discussion 
In this study we described a number of parameters which may affect the precision and power 
of CRR harm estimates in general practice. We combined a wide range of different parameter 
values into different CRR scenarios and used computer simulation to establish which ones 
would yield harm rate estimates with acceptable precision and adequate power. From this, we 
derived a formula which we used to calculate the minimum number of harm incidents that 
had to be detected during any CRR process to ensure the harm estimates had acceptable 
precision and adequate power. We found that any CRR scenario which detected a minimum 
of 100 harm incidents would have harm rate estimates with the level of precision we pre-
specified. Using the formula and our simulated data, we calculated that detecting a 50% and 
20% reduction in harm with acceptable power would require CRR scenarios to detect at least 
100 and 500 harm incidents respectively, over a given period of time. 
The practical implication of the CRR scenarios which assures harm rate estimates with 
acceptable precision (as defined by us) is that approximately 2000 records (assuming a high 
baseline harm rate) increasing to 20 000 records (assuming a low harm rate) would have to be 
reviewed. If the aim of the CRR is to detect changes in harm rates with adequate power over 
time as many as 120 000 records may have to be reviewed, depending on the prevalence of 
the harm in the patient population of interest. Different parameter values can be combined 
into different CRR scenarios by health care researchers, clinicians, policy makers and others 
to fit their aims and resources. By applying our formula, they could ensure the harm estimates 
of these potential different CRR scenarios will have adequate precision and acceptable 
power. 
Comparison with the literature 
The vast majority of studies with a CRR methodology aim to detect either patient safety 
incidents (PSIs) in general, or more specific subsets of PSIs such as harm, adverse drug 
reactions or errors, to estimate a harm rate for a defined geographical location or clinical 
department at specified points in time. Our non-systematic search of the relevant international 
literature [1,3] did not uncover a single study in which the precision of these reported rates 
was either considered or documented. In addition, none seem to have explicitly considered 
the required parameter values of their CRR method. Instead, the size of the patient record 
samples seemed determined only by resources, time and feasibility concerns. While this 
observation does not necessarily imply that all previous harm rate estimates were imprecise, 
our findings suggest that any CRR which detected less than 100 harm incidents may not have 
had adequate precision (as defined by us). 
To illustrate this point further, we provide three practical examples. Example one: Singh and 
colleagues measured the adverse drug event rate amongst older patients with established 
cardiovascular disease by reviewing a 12 month period in 393 pre-screened trigger positive 
records from six general practices in the UK [18]. They found 232 adverse drug events, of 
which 92 were judged preventable, with an estimated rate of 24.6 preventable adverse drug 
incidents/100patients/year. Applying our formula to their CRR method and findings suggest 
their estimated rate has adequate precision (as defined by us). Example two: Gaal and 
colleagues reviewed 1000 unique medical records in Dutch general practice, over a twelve 
month period, and estimated a rate of 21.1 patient safety incidents/100patients/year (CI 18.5-
24.1), and 5.8 harm events/100patients/year [19]. Applying our formula to their CRR method 
and findings suggest the estimated patient safety incident (PSI) rate is precise but the harm 
rate estimate may not be. Example three: De Wet and Bowie reviewed a 12-month period in 
each of 100 records randomly sampled in five participating practices in Scotland [17]. 
Overall, 64 PSIs were found, which is less than the 100 harm incidents our formula suggests 
for acceptable precision. 
Only a tiny minority of studies using the CRR method has aimed to measure reductions in 
harm rates over time. They were all conducted in secondary care settings and to our 
knowledge there has been none in primary care. Carter described the experiences of a 
hospital in the UK with the global trigger tool over a five year period [31]. While it 
‘appeared’ that the incidence of ‘more serious’ events reduced and ‘more minor’ harm 
incidents increased, the changes were not quantified. Landrigan and colleagues’ review of 
2341 admissions to 10 USA hospitals over a six year period was the largest study of its type 
when it was published, but failed to detect a significant reduction in the rate of harm during 
this period [8,32]. Applying our formula (which suggests detecting a 20% change in harm 
would require a CRR to detect at least 500 preventable harm incidents) to their findings 
suggests at least two possibilities: either there was no reduction in harm, or there was a small 
reduction but the sample was insufficiently powered to detect it. 
Our simulations represent ‘best case’ scenarios and likely underestimate the amount of 
records that may have to be reviewed. While we know that a substantial proportion of PSI 
may not be preventable because they originated in different settings, are recognized as side 
effects of appropriate treatment or are dependent on patient factors, this was not directly 
controlled for in our simulations. Current estimates suggest between 10 and 50% of detected 
harm incidents may be preventable [9,18,33,34]. Therefore, when researchers or reviewers 
attempt to measure reductions in harm over time, they have to remove, or at the very least 
consider, what proportion of the detected harm incidents are likely to be’non-preventable’. 
Otherwise, the observed reduction will appear ‘smaller’ (as a percentage) than it actually was, 
and their CRR scenario’s power to detect the change will also be decreased. 
To illustrate this point further, consider the study conducted by Takata and colleagues as a 
practical example. They detected 107 adverse drug events, of which 24 (22%) were judged 
preventable in their review of 960 paediatric records from 12 USA hospitals [16]. If they 
aimed to reduce the number of preventable incidents by an ambitious 50% (e.g. a reduction 
from 24 to 12 incidents) over a given period of time, this reduction would ‘only’ be 11.2% of 
their overall ADE rate. Our findings suggest this would require a CRR of many thousands of 
records, and certainly much more than if their aim had been a reduction of 50% in the overall 
rate. 
Potential application of findings 
There is considerable political and policy interest in a measure to reliably quantify and then 
track rates of harm in primary care records over time. The ideal attributes of such a measure 
are that it should be: relevant; valid; reliable; discriminative; credible; timely; feasible; 
accessible; and actionable [35]. CRR has most of these attributes, but may be limited by 
feasibility concerns. Our findings are the first known attempt to quantify the minimum CRR 
parameter values which impact on feasibility (e.g. number of practices reviewing records and 
number of records reviewed per practice) and may therefore help to inform the discussion and 
planning of health care policy makers and leaders who are interested in measuring harm in 
general practice. 
While our findings suggest a single general practice cannot feasibly measure its rate of harm 
with acceptable precision or adequate power, we provided many CRR scenarios that would 
yield harm rate estimates with adequate precision and acceptable power if implemented at 
national or regional level and a formula to test any other, proposed CRR adaptations. 
At national level, there are 1003 general medical practices in Scotland [22]. Our findings 
suggest that if at least 300 practices each reviewed 25 records twice over a given period of 
time (say 12 months), the CRR sample yield harm rate estimates with acceptable precision 
and would have adequate power to detect a 50% reduction in ‘any’ assumed baseline harm 
rate if it occurred during this period. Smaller changes in harm rates could be detected if every 
practice in Scotland participated, although engagement would likely have be sought through 
contractual incentivisation. 
Let us consider two examples at the regional level. Example one: A Scottish regional Health 
Board with 100 general medical practices aims to estimate their harm rate with acceptable 
precision. If they assume a real (baseline) harm rate of 10 incidents/100 patients/year, our 
formula indicates that each practice will have to review 50 records to achieve this aim. If the 
Health Board assume a lower harm rate of 5 incidents/100patients/year or selects a less harm 
prone patient population, each practice will have to review 100 records to achieve a harm rate 
estimate with acceptable precision. Example two: A Scottish regional Health Board wants to 
estimate the harm rate in their region which has 57 general practices. If they assume a 
baseline harm rate of 5 incidents/100 patients/year, each practice would have to review 150 
records to estimate the harm rate with acceptable precision. 
Measuring at regional and national level will require substantial investment in training and 
support, allocation of additional resources and protected time for clinician reviewers. 
Strengths and limitations 
Our findings were derived by aggregating the results of multiple simulated data sets for 
different CRR scenarios derived from predefined parameters and parameter values. Our 
assumptions about these parameter values were informed by practical experience and 
available literature. Given that the available evidence of harm prevalence and preventability 
varies widely, our choices of harm rates and potential reductions in harm are therefore likely 
to include overestimations of incidence and reductions. 
Our statistical method allowed simulation of complex scenarios, but the data remains 
simulated and at best a simplified and imprecise presentation of reality. We accepted the 
principle that the same patient may suffer more than one incident during a review period. 
This meant that data had to be treated as ‘count’ rather than binary. The consequences were 
that harm rates had to be expressed as rates (i.e. incidents/100 patients/year) and not 
percentages, and sensitivity, specificity and predictive value could not be calculated. Potential 
inter-rater bias and intra-rater error (inconsistency) were accounted for by ‘including’ it as 
part of the inter-practice variation in harm rate. We assumed the same patients’ records were 
reviewed at the beginning and end of the study period. This reduced inter-patient variation 
and increased power. 
We also identified a problem of substantial positive bias in harm rate estimates where there 
are high levels of inter-patient variation. The standard approach of quantifying and adjusting 
for inter-patient variation was not feasible due to the very low numbers of harm incidents in 
some CRR scenarios. These results suggest that estimates of harm rates from CRRs could 
contain unquantifiable upward bias due to unknown levels of inter-patient variation. This is a 
problem that will affect real studies and not an artefact of our analysis. It is a consequence of 
making estimates from multilevel data where the numbers of events are too small to allow the 
multilevel effects to be adjusted for. The sample sizes required to adjust for these effects were 
beyond the realistic range explored here and may be unfeasible. The implications of this 
inability to estimate random effects go beyond bias in harm rate estimates to scenarios where 
variation between practices is of primary interest rather than simply a parameter to be 
adjusted for. If the aim of CRR was to determine whether some practices have significantly 
higher harm rates than others, or if the harm rates of some practices are changing (increasing 
or decreasing) faster than others, considerably larger numbers of patient safety incidents 
would have to detected than in our simulations. This would require increasing the number of 
records reviewed, lengthening the review period and/or selecting an unusually harm-prone 
population of patients. 
Future research 
We simulated CRR to detect changes over a single time period. In our scenarios power was 
maximised by reviewing records at only two time points - the beginning and end of a twelve 
month period. However, many patient safety programs may not be time-limited or will 
measure harm at multiple time points. The availability of data at additional time points will 
allow the detection of trends. Monte Carlo simulations could be used in future research to 
optimise experimental design for such longitudinal scenarios. 
The relationship between measurement and improvement, and the challenge of ‘getting one 
to follow the other’ has previously been described [35]. We still do not know which 
interventions can successfully improve patient safety in general practice. What little evidence 
there is suggests successful interventions will likely require a multi-method approach, 
rigorous evaluation and small, local clinician-led pilots [36]. Future research should therefore 
examine the utility of CRR as a learning and improvement tool, ‘…working on the nuts and 
bolts of how we turn measurement for improvement into tangible change in practice… [35]’ 
Other potential research questions include: the effects of inter-patient and practice variation 
on estimated harm rates; and what the ideal mixture of parameter values (number practices, 
records reviewed in each practice and review time per record) are to detect the minimum 
number of harm incidents to ensure acceptable precision and adequate power. Finally, our 
statistical model and formula needs to be validated further through practical application. 
Conclusion 
This study is the first known attempt to describe the minimum parameter values of any CRR 
which will ensure its harm rate estimates have adequate precision and adequate power. We 
derived a formula which allows calculation of the minimum number of harm incidents which 
have to be detected with a CRR to ensure adequate precision and acceptable power. Our 
findings have practical implications for health care decision-makers, leaders and researchers 
aiming to measure harm at regional or national level. 
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Additional file 1: Table S1 The precision$ of selected clinical record review (CRR) 
scenarios’ estimated harm rates. Scenarios vary by numbers of practices reviewing records, 
number of records reviewed in each practice and real harm rates (rHR)*. The median rate 
ratios (MRR) between patients** and practices are 1.2 and 1.2 respectively. The results are 
from the beginning of the simulated 12-month period. Figure S1. Clinical record review 
(CRR) scenarios which yielded harm rate estimates with acceptable precision, e.g. estimation 
errors < ±25% of the real harm rate (rHR). The lines and the zone above and to the right of 
each line represent those CRR scenarios with acceptable precision. Scenarios vary according 
to number of practices reviewing records, number of records reviewed per practice and the 
rHR (indicated by numbers on the lines and measured in incidents/100 patients/year. The 
median rate ratios (MRR) between patients and practices are 1.2 and 1.2 respectively. The 
results are for the beginning of the simulated twelve month period. Table S2. Power (%)* of 
selected clinical record review (CRR) scenarios to detect a reduction (R) in the real harm rate 
(rHR) over a twelve month period. Scenarios vary by numbers of practices reviewing records, 
number of records reviewed in each practice and rHR. Median rate ratios (MRR) between 
patients and practices are 1.2 and 1.2 respectively. Figure S2. Clinical record review (CRR) 
scenarios with adequate power (≥80%) to detect a 50% (solid line) or 20% (dashed line) 
reduction in real harm rates (rHR) over a twelve month period. The lines and the zone above 
and to the right of each line represent CRR scenarios with adequate power. Scenarios vary 
according to number of practices reviewing records, number of records reviewed per practice 
and the rHR (indicated by numbers on the lines and measured in incidents/100 patients/year. 
The median rate ratios (MRR) between patients and between practices were 1.2 and 1.2 
respectively. Table S3. The 95% confidence interval coverage and bias of selected clinical 
record review (CRR) scenarios’ estimated harm rates. Coverage estimates that are 
significantly different from 95% are underlined. Scenarios vary by numbers of practices 
reviewing records, number of records reviewed in each practice and real harm rates (rHR)*. 
The median rate ratios (MRR) between patients and practices are 1.2 and 1.2 respectively. 
The results are from the beginning of the simulated 12-month period. Table S4. The 95% 
confidence interval coverage and bias of selected clinical record review (CRR) scenarios’ 
estimated harm rates. Coverage estimates that are significantly different from 95% are 
underlined. Scenarios vary by numbers of practices reviewing records, number of records 
reviewed in each practice and real harm rates (rHR)*. The median rate ratios (MRR) between 
patients and practices are 2 and 1.2 respectively. The results are from the beginning of the 
simulated 12-month period. 
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Records reviewed (n) during the full 12−month simulated period
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